Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Convalescent Plasma Clear all
No Longer Available No phase listed Expanded access

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207
View directory record Official record
Conditions
COVID, Sars-CoV2, Corona Virus Infection
Interventions
Convalescent Plasma
Biological
Lead sponsor
Jonathan Gerber
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 22, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional

Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

NCT04361253
View directory record Official record
Conditions
COVID, Infectious Disease
Interventions
High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP)
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Months and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19

NCT04438057
View directory record Official record
Conditions
COVID-19
Interventions
CCP
Biological
Lead sponsor
Metro Infectious Disease Consultants
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Burr Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 22, 2026, 8:14 PM EDT
No Longer Available No phase listed Expanded access

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

NCT04360486
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Anti-Sars-CoV-2 Convalescent Plasma
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
26
States / cities
Oceanside, California • San Diego, California • Fort Carson, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 22, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

NCT04432272
View directory record Official record
Conditions
COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

NCT04397757
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

NCT04374565
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
Interventions
High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Jul 22, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Anti-SARS-CoV-2 Immune Plasma

NCT04344977
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Torrance, California • Miami, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jul 22, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

NCT04343755
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional

COVID-19 Plasma Collection

NCT04344015
View directory record Official record
Conditions
COVID-19
Interventions
Plasma Donation
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers

NCT04334876
View directory record Official record
Conditions
SARS-CoV-2
Interventions
SARS-CoV-2 IgG Antibody Testing Kit
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992
View directory record Official record
Conditions
Covid19
Interventions
COVID 19 Convalescent Plasma
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

NCT04392232
View directory record Official record
Conditions
Coronavirus, COVID-19, Convalescent Plasma
Interventions
Convalescent Plasma
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
16 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Jul 22, 2026, 8:14 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection

NCT06084351
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Standard of Care
Drug · Other
Lead sponsor
Larkin Community Hospital
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 22, 2026, 8:14 PM EDT
No Longer Available No phase listed Expanded access

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, SARS-CoV Infection
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

NCT04354831
View directory record Official record
Conditions
COVID-19
Interventions
anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Jul 22, 2026, 8:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472
View directory record Official record
Conditions
Covid-19
Interventions
Convalescent plasma transfusion
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Jul 22, 2026, 8:14 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04338360
View directory record Official record
Conditions
COVID19
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
U.S. locations
12
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Early Phase 1 Interventional Results available

COVID-19 Convalescent Plasma

NCT04340050
View directory record Official record
Conditions
Coronavirus
Interventions
anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 22, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

NCT04513158
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Joseph M. Flynn, D.O., MPH
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 22, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

NCT04348656
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma
Biological
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
16 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jul 22, 2026, 8:14 PM EDT